Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Orion announces Stavelo trial did not have desired outcome

Orion announces Stavelo trial did not have desired outcome

24th February 2009

Orion has announced that a clinical study for a treatment intended to assist Parkinson’s disease (PD) patients did not have the desired outcome.

The propriety drug Stalevo (levodopa, carbidopa and entacapone) was tested on 747 adults suffering with early forms of the illness who required levodopa therapy.

It was found that it did not delay the arrival of involuntary movements, known as dyskinesia.

The European Medicines Agency (EMEA) is currently reviewing an application to extend the indication of the drug to patients.

This consideration is due to the favourable results the medication achieved in a previous study conducted by Novartis, the firm’s marketing partner for the product, in Europe and the United States.

PD is a progressive disorder of the central nervous system, the cause of which is unknown. Sufferers can experience tremors, balance problems and slowness.

With headquarters in Finland, Orion is a European pharmaceuticals and diagnostics company that employs around 3,100 staff. It states it is dedicated to treat and prevent disease by discovering and developing medication for a global market.

In 2008, it invested 99 million euros (86.87 million pounds) in research and development.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.